Lee's Pharmaceutical Holdings (HKSE:00950) Change In Working Capital : HK$0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Change In Working Capital?

Lee's Pharmaceutical Holdings's change in working capital for the quarter that ended in Dec. 2024 was HK$0 Mil.

Lee's Pharmaceutical Holdings's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-51 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Lee's Pharmaceutical Holdings Change In Working Capital Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Change In Working Capital Chart

Lee's Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-71.28

64.52

-15.01

-78.33

-50.99

Lee's Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Lee's Pharmaceutical Holdings Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Lee's Pharmaceutical Holdings Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Change In Working Capital

Traded in Other Exchanges

N/A

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Executives

Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Leelalertsuphakun Wanee	2101 Beneficial owner
Huang Zuie-chin	2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky	2202 Interest of your spouse
Li Xiaoyi	2101 Beneficial owner
Lee Siu Fong	2101 Beneficial owner
Ubs Group Ag	2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p.	2101 Beneficial owner
Panacea Innovation Limited	2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Apta Finance Sa	2201 Interest of corporation controlled by you
Qualister Sa	2101 Beneficial owner
Paponi Claudia	2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines